ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 4

Interferon Therapy in PV

, , , ,

Panelists discuss additional data supporting the use of alternative agents and treatment pathways for polycythemia vera (PV), including the role of ropeginterferon alfa-2b (Ropeg alfa-2b) based on findings from the PROUD-PV /CONTINUATION-PV studies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Initial Treatment Strategies for Polycythemia Vera
    EP. 2: Cytoreductive Therapy in PV Treatment Paradigm
    EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates
    Now Viewing
    EP. 4: Interferon Therapy in PV
    EP. 5: Safety Considerations for PV Therapy
    EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
    EP. 7: Interferon Real- World Treatment Patterns in PV
    EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
    EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
    EP. 10: An Overview to Myelofibrosis and Disease Risk
    EP. 11: Treatment Goals for Myelofibrosis
    EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials
    EP. 13: Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib
    EP. 14: Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice
    EP. 15: Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches
    EP. 16: Myelofibrosis at ASH 2024: Key Updates and Emerging Therapies
    EP. 17: MPN Milestones of 2024 and What’s Next for 2025

    Video content above is prompted by the following:

    • Please comment on additional data supporting the use of other agents/pathways.
    • PROUD-PV/CONTINUATION-PV, Ropeginterferon alfa-2b (Ropeg alfa-2b) in PV
    x